Cargando…
P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA
Autores principales: | Stegelmann, F., Jahn, E., Koschmieder, S., Heidel, F., Hochhaus, A., Hebart, H., Isfort, S., Reiter, A., Bangerter, M., Waller, C. F., Wolleschak, D., Scheid, C., Göthert, J., Schafhausen, P., Kindler, T., Radsak, M. P., Gattermann, N., Möhle, R., von Bubnoff, N., Schrade, A., Brümmendorf, T., Döhner, H., Griesshammer, M., Döhner, K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429480/ http://dx.doi.org/10.1097/01.HS9.0000847088.09306.08 |
Ejemplares similares
-
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
por: Koschmieder, Steffen, et al.
Publicado: (2022) -
Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN
por: Kricheldorf, Kim, et al.
Publicado: (2021) -
Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
por: Stegelmann, Frank, et al.
Publicado: (2023) -
Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry
por: Gecht, Judith, et al.
Publicado: (2021) -
Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
por: Crodel, Carl C., et al.
Publicado: (2020)